Zenas BioPharma nomme Simon Lowry, M.D. au poste de directeur médical

WALTHAM, Mass. et SHANGHAI, Chine, 07 sept. 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de thérapies immunitaires pour les patients dans le besoin à travers le monde, a annoncé aujourd’hui la nomination de Simon Lowry, M.D., au poste de directeur médical de la société. Le Dr Lowry apporte plus de 20 ans d’expertise clinique dans la conception et l’exécution de programmes cliniques de stade précoce à avancé à Zenas, où il dirigera les fonctions cliniques, médicales et de pharmacovigilance de la société au niveau international.

« Nous sommes ravis d’accueillir le Dr Lowry au sein de Zenas à ce moment crucial pour la société, alors que nous commençons deux essais d’enregistrement de phase trois pour notre principal produit candidat, l’obexelimab, au quatrième trimestre de cette année, et que nous entamons les premiers essais cliniques sur l’homme pour plusieurs programmes en cours », a déclaré Hua Mu, M.D., Ph. D, président-directeur général de Zenas. « Le leadership éprouvé du Dr Lowry, sa vaste expérience du développement clinique et sa grande expérience en matière d’essais cliniques à l’échelle mondiale renforceront davantage notre capacité à mener à bien notre mission, qui consiste à transformer la vie des patients dont les besoins médicaux ne sont pas satisfaits, en leur proposant les meilleurs traitements immunitaires de leur catégorie. »

Le Dr Simon Lowry a ajouté : « De nombreux patients atteints de maladies rares et auto-immunes ont besoin d’options thérapeutiques nouvelles et efficaces. L’équipe de Zenas, très expérimentée et talentueuse, a considérablement développé son portefeuille en très peu de temps, et je suis impatient de diriger l’avancement continu des programmes cliniques de Zenas jusqu’à la commercialisation, tout en renforçant le portefeuille de programmes innovants de la société. »

Le Dr Lowry est un médecin possédant 20 ans d’expérience dans des sociétés pharmaceutiques et biotechnologiques importantes et émergentes, où il a dirigé des programmes de développement fructueux, des équipes d’affaires cliniques et médicales, et interagi avec des organismes de réglementation dans plusieurs domaines de la médecine, y compris la rhumatologie, l’immunologie et l’ophtalmologie. Avant de rejoindre Zenas, le Dr Lowry était directeur médical chez Kinevant Science, une société biopharmaceutique au stade clinique, spécialisée dans le traitement des maladies inflammatoires et auto-immunes rares. Le Dr Lowry était auparavant responsable de la R&D en immunologie chez Roivant Sciences, où il dirigeait tous les actifs de l’immunologie en phase de développement clinique, et était un membre clé de l’équipe de direction. Il a également occupé le poste de directeur médical chez Sun Pharma North America, où il était responsable de quatre domaines thérapeutiques de marque (immunologie et dermatologie, ophtalmologie, neurologie et oncologie), et a dirigé tous les aspects du développement et des fonctions médicales (y compris le développement clinique, les informations médicales, la médecine de terrain, La recherche sur l’économie et les résultats de la santé (HEOR), les publications/communications médicales et les opérations). Au début de sa carrière, il a travaillé chez Novartis, où il a occupé le poste de vice-président, directeur de franchise des affaires médicales mondiales, immunologie et dermatologie, et chez Pfizer, où il a occupé des postes à responsabilité croissante, notamment celui de vice-président du groupe des affaires médicales en oncologie.

Avant sa carrière dans le secteur pharmaceutique/biotechnologique, le Dr Lowry a pratiqué la médecine interne dans diverses institutions au Royaume-Uni et en Australie. Il a obtenu son BA au Trinity Hall, de l’université de Cambridge, au Royaume-Uni et son diplôme médical MB BChir à la Cambridge University School of Clinical Medicine.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le monde entier. Avec un développement clinique et des activités aux États-Unis et en Chine, Zenas fait rapidement progresser un important programme de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma Appoints Simon Lowry, M.D. as Chief Medical Officer

WALTHAM, Mass. and SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the appointment of Simon Lowry, M.D., as the company’s Chief Medical Officer. Dr. Lowry brings over 20 years of broad clinical expertise in the design and execution of early to late-stage clinical programs to Zenas, where he will lead the company’s global clinical, medical affairs, and pharmacovigilance functions.

“We are delighted to welcome Dr. Lowry to Zenas at this pivotal time for the company as we commence two phase three registration trials for our lead product candidate, obexelimab, in the fourth quarter of this year and initiate first-in-human clinical trials for multiple pipeline programs,” said Hua Mu, M.D., Ph. D, Chief Executive Officer at Zenas. “Dr. Lowry’s proven leadership, broad clinical development background, and extensive global clinical trial experience will further strengthen our ability to execute on our mission to transform the lives of patients with unmet medical needs by bringing best-in-class immune-based therapies to patients.”

Dr. Simon Lowry added, “There are many patients with autoimmune and rare diseases in need of effective new treatment options. The deeply experienced and talented Zenas team has made impressive progress advancing the company’s pipeline in a very short period of time, and I look forward to leading the ongoing advancement of Zenas’ clinical programs through commercialization while further expanding the company’s pipeline of innovative programs.”

Dr. Lowry is a medical doctor with 20 years of experience at large and emerging pharmaceutical and biotechnology companies directing successful development programs, leading clinical and medical affairs teams, and interacting with regulatory agencies across multiple areas of medicine, including rheumatology, immunology, and ophthalmology. Prior to joining Zenas, Dr. Lowry was Chief Medical Officer at Kinevant Science, a clinical-stage biopharmaceutical company focused on treating rare inflammatory and autoimmune diseases. Dr. Lowry was previously Head of Immunology R&D at Roivant Sciences, leading all development stage immunology assets into clinical development, and served as a key member of the leadership team. He also served as Chief Medical Officer at Sun Pharma North America, where he was responsible for four branded therapeutic areas (Immunology & Dermatology, Ophthalmology, Neurology and Oncology), and led all aspects of development and medical functions (including clinical development, medical information, field medical, HEOR, publications / medical communications, and operations). Early in his career, he worked at Novartis, where he served as Vice President, Global Medical Affairs Franchise Head, Immunology & Dermatology, and Pfizer, where he served in roles of increasing responsibility, including as Vice President, Oncology Medical Affairs Group Leader.

Prior to his pharmaceutical/ biotechnology career, Dr. Lowry practiced internal medicine at various institutions in the UK and Australia. He received his BA from Trinity Hall, Cambridge University, UK and his MB BChir medical degree from Cambridge University School of Clinical Medicine.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients around the world. With clinical development and operations in the US and China, Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Zenas BioPharma Nomeia Simon Lowry, M.D. para Diretor Médico

WALTHAM, Mass. e SHANGHAI, China, Sept. 07, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas, anunciou hoje a nomeação de Simon Lowry, MD para seu Conselho Diretor. O Dr. Lowry tem mais de 20 anos de ampla experiência clínica na concepção e execução de programas clínicos de estágio inicial a final na Zenas, onde ele passará a liderar as funções globais de clínica, assuntos médicos e farmacovigilância da empresa.

“Estamos muito contentes em receber o Dr. Lowry na Zenas neste momento crucial para a empresa, quando damos início a dois testes de registro de fase três do nosso principal candidato a produto, obexelimabe, no quarto trimestre deste ano, e aos primeiros testes clínicos em humanos de vários programas de pipeline”, disse Hua Mu, M.D., Ph.D., Diretor Executivo da Zenas. “A liderança comprovada do Dr. Lowry, seu amplo histórico de desenvolvimento clínico e extensa experiência com ensaios clínicos globais irão fortalecer ainda mais nossa capacidade de executar nossa missão de transformar a vida dos pacientes com necessidades médicas não atendidas, com a oferta das melhores terapias imunológicas aos pacientes.”

O Dr. Simon Lowry acrescentou: “Há muitos pacientes com doenças autoimunes e raras que precisam de novas opções de tratamento eficazes. A equipe profundamente experiente e talentosa da Zenas fez um progresso impressionante ao avançar no pipeline da empresa em um período muito curto de tempo, e estou pronto para liderar o avanço contínuo dos programas clínicos da Zenas com a sua comercialização e maior expansão do pipeline de programas inovadores da empresa.”

O Dr. Lowry tem 20 anos de experiência com grandes empresas farmacêuticas e de biotecnologia emergentes, tendo dirigido programas de desenvolvimento bem-sucedidos, liderado equipes de assuntos clínicos e médicos, e interagido com agências reguladoras em várias áreas da medicina, incluindo reumatologia, imunologia e oftalmologia. Antes de ingressar na Zenas, o Dr. Lowry foi Diretor Médico da Kinevant Science, uma empresa biofarmacêutica de estágio clínico focada no tratamento de doenças inflamatórias e autoimunes raras. Anteriormente, o Dr. Lowry foi Chefe de Pesquisa e Desenvolvimento em Imunologia da Roivant Sciences, liderando todos os ativos de imunologia em estágio de desenvolvimento para o desenvolvimento clínico, e serviu como um membro-chave da equipe de liderança. Ele também atuou como Diretor Médico na Sun Pharma North America, onde foi responsável por quatro áreas terapêuticas de marca (Imunologia e Dermatologia, Oftalmologia, Neurologia e Oncologia) e liderou todos os aspectos do desenvolvimento e funções médicas (incluindo desenvolvimento clínico, informações médicas, medicina de campo, HEOR, publicações/comunicações médicas e operações). No início da sua carreira, ele trabalhou na Novartis, onde atuou como Vice-Presidente, Chefe de Franquia de Assuntos Médicos Globais, Imunologia e Dermatologia, e na Pfizer, onde atuou em funções de responsabilidade crescente, incluindo como Vice-Presidente, Líder do Grupo de Assuntos Médicos de Oncologia.

Antes da sua carreira farmacêutica/biotecnológica, o Dr. Lowry exerceu medicina interna em várias instituições no Reino Unido e na Austrália. Ele é formado em Medicina pela Trinity Hall, Cambridge University e pela Cambridge University School of Clinical Medicine no Reino Unido.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes em todo o mundo. Com desenvolvimento clínico e operações nos EUA e na China, a Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

IPLOOK Chosen by Oceanlink to Enable the Delivery of 4G Mobile Network on Pacific Islands

IPLOOK’ s MNO solution allows Oceanlink to quickly and economically deliver 4G network services to its mobile users; Achieving IPLOOK’ s first commercial 2G&3G&4G LTE deployment (CSFB Feature) in Kiribati

HONG KONG, Sept. 7, 2022 /PRNewswire/ —  IPLOOK Technologies, the leader in end-to-end LTE/5G mobile core network vendor, announced it has been chosen by Oceanlink, a Mobile Network Operator (MNO) in Kiribati, to provide its 4G mobile core network for commercial deployment on Pacific Islands. This deployment enables Oceanlink to address the high-performance and stable network demands, expanding its service offerings to customers.

On the islands of Kiribati, the legacy 2G/3G network connection is not developed as quickly as the growing market demand for high-speed internet and multiple media services. By deploying IPLOOK’s carrier-grade  EPC and IMS platform, Oceanlink achieved a swift rollout of the new-built 4G commercial network while significantly lowering the total cost of ownership (TCO) and reducing overall time to market, delivering its customers a truly seamless connectivity experience with less network disruption.

“To satiate customers’ demands for highly reliable network connectivity, we chose IPLOOK as our partner. Backed up by an excellent team to undertake this network transformation, we are well-positioned to address future growth and expansion,” said Liyong Liang, CTO of ACCLINKS.

“We are excited to work with ACCLINKS to expand mobile services and cost-effectively scale their networks by leveraging our MNO solution,” said Owen Ouyang, Region Director in the MENA region of IPLOOK, “This cooperation is a prime example of our high-quality and easy-to-deploy network solution that accelerates operators’ ability to create revenue opportunities.”

About Oceanlink

ACCLINKS (Branded as “Oceanlink”) has been serving customers on Pacific Islands since 2003. The company establishes trust with customers through professional services, customized products and quick response. ACCLINKS provides high quality products and top level professional services.

More info at http://www.acclinks.com/.

About IPLOOK

Founded in 2012, IPLOOK is an industry-leading end-to-end, cloud-based mobile network solution provider. IPLOOK’ s highly scalable virtualized 3G/4G/5G core network software products can be deployed in the deployment scenarios for Mobile Network Operators (MNO), Mobile Virtual Network Operators (MVNO), Wireless Internet Services Providers (WISP) and Enterprises.

Reach out more at https://www.iplook.com/. Follow IPLOOK on LinkedIn @IPLOOK Technologies

Contact us:

E-mail: info@iplook.com

Tribert Rujugiro Ayabatwa Welcomes the East African Court of Justice Ruling that Rwanda Government’s Seizure of his Trade Union Centre Mall Was Illegal

TORONTO, Sept. 6, 2022 /PRNewswire/ — Entrepreneur and philanthropist Tribert Rujugiro Ayabatwa is pleased to announce that on August 30, 2022, the East African Court of Justice (EACJ) ruled that Rwanda government’s seizure and auctioning his Union Trade Centre (UTC) Mall were illegal. EACJ awarded Ayabatwa US$1 million, 6% interest and court costs. The government seized the US$20 million Mall in 2013, alleging that UTC was ‘abandoned’ because Ayabatwa who is Rwandan-born resided outside Rwanda. UTC was at the time a thriving business, hosting 80 businesses with nearly 500 employees, managed by a strong local team in good standing with Rwandan authorities. Then in August 2015, the government declared UTC a tax defaulter of US$1.4 million, an absurd claim, since the Mall was managed by the Rwandan state. Two years later, the government auctioned UTC for a mere US$8 million, less than half its actual value.

Union Trade Centre Mall

Ayabatwa took the government to EACJ, which ruled in 2020 that seizure and auctioning UTC were illegal. The government was ordered to account for rental and sale proceeds of UTC from 2013 and to compensate Ayabatwa for damages amounting to US$500,000 and 6% annual interest from the date of judgment. Ayabatwa appealed the ruling, however, because the Court did not restore his ownership of UTC. That is when the government fabricated a new absurd allegation that Ayabatwa and his associates had embezzled US$458,058 from UTC in 2011. The cited ‘crime’ was in fact a loan acquired during the construction of UTC Mall. Now, the Rwandan government has once again lost the UTC Mall case. Ayabatwa welcomed the 30 August 2022 Court ruling, remarking that “there are times when we are powerless to prevent injustice, but with truth on your side, justice always prevails.”

About Tribert Rujugiro Ayabatwa

Tribert Rujugiro Ayabatwa is a successful entrepreneur and philanthropist from Rwanda. He is founder of Pan-African Tobacco Group, Africa’s largest indigenous manufacturer of tobacco products in nine African countries and in the United Arab Emirates, trading across eastern, western and southern Africa. Ayabatwa is one of Africa’s leading philanthropists, assisting communities to uplift themselves in food security, access to clean water, reforestation, education, and engineering internships.

Pan-African Tobacco Group
info@ptg-hld.com
www.ptg-hld.com

Photo – https://mma.prnewswire.com/media/1892959/Tribert_Rujugiro_Ayabatwa__UTC_founder_Tribert_Rujugiro_Ayabatwa.jpg

David Himbara, Pan-African Tobacco Group, info@ptg-hld.comwww.ptg-hld.com

WMO: Climate change in Africa can destabilize ‘countries and entire regions’

Water stress and hazards like withering droughts and devastating floods are hitting African communities, economies and ecosystems hard, according to a new report launched on Thursday by the World Meteorological Organization (WMO).

The State of the Climate in Africa 2021 reveals that rainfall patterns are disrupted, glaciers are disappearing and key lakes are shrinking.

And rising water demand, combined with limited and unpredictable supplies, threatens to aggravate conflict and displacement.

“The worsening crisis and looming famine in the drought-stricken Horn of Africa shows how climate change can exacerbate water shocks, threatening the lives of hundreds of thousands of people and destabiliizing communities, countries and entire regions,” said WMO Secretary-General Petteri Taalas.

Temperature trends

The report shows how extreme weather and climate change are undermining human health and safety, food and water security, and socio-economic development.

While Africa accounts for only about two to three per cent of global greenhouse gas emissions, it suffers disproportionately from it.

With a special focus on water, The State of the Climate reveals that high water stress is estimated to affect about 250 million people on the continent and displace up to 700 million individuals by 2030.

Four out of five African countries are unlikely to have sustainably managed water resources by 2030.

“Africa’s climate has warmed more than the global average since pre-industrial time,” warned Mr. Taalas, noting that the sea level rise along African coastlines is faster than the global mean.

He observed that that this is contributing to increases in the frequency and severity of coastal flooding and erosion, and salinity in low-lying cities.

“Changes in continental water bodies have major impacts on the agriculture sector, ecosystems, biodiversity,” said the WMO chief.

Making changes

Currently only 40 per cent of the African population has access to early warning systems against extreme weather and climate change impacts.

At the request of Secretary-General António Guterres, WMO is spearheading a campaign to ensure universal access to early warnings in the next five years.

Meanwhile, climate action is gaining momentum.

More than 40 African States have revised their national climate plans to make them more ambitious and add greater commitments to climate adaptation and mitigation.

The State of the Climate report makes a number of recommendations, including to strengthen early warning systems, increase transboundary cooperation, data exchange and knowledge sharing.

It underscores that the need for more investment in adaptation is crucial, as is a concerted drive towards more integrated water resource management.

The report was launched with an accompanying digital story map at a Ministerial Meeting on Integrated Early Warning and Early Action System initiative in Maputo, Mozambique.

Source: United Nations

Queen Elizabeth II: ‘Reassuring presence’ throughout decades of ‘sweeping change’

Secretary-General António Guterres expressed on Thursday, his deep sadness at the passing of Her Majesty Queen Elizabeth II, the Queen of the United Kingdom of Great Britain and Northern Ireland.

As the UK’s longest-lived and longest-reigning Head of State, the 96-year-old Queen was widely admired for her “grace, dignity, and dedication around the world,” he said in a statement.

“She was a reassuring presence throughout decades of sweeping change, including the decolonization of Africa and Asia and the evolution of the Commonwealth”.

‘Good friend’ to Organization

Queen Elizabeth II was “a good friend of the United Nations”, he said, recalling that she had visited New York Headquarters twice, more than fifty years apart.

“She was deeply committed to many charitable and environmental causes and spoke movingly to delegates at the COP26 climate talks in Glasgow,” recalled the UN chief.

“I would like to pay tribute to Queen Elizabeth II for her unwavering, lifelong dedication to serving her people”.

‘Devotion and leadership’

Mr. Guterres extended his sincere condolences to her bereaved family, the Government and people of the United Kingdom of Great Britain and Northern Ireland, and the wider Commonwealth of Nations.

“The world will long remember her devotion and leadership,” he concluded.

Last days in Scotland

Queen Elizabeth II died on the estate known as Balmoral Castle in Scotland, which had served as a royal summer retreat.

Over the past year, she had delegated some royal duties to her eldest son, Prince Charles, the heir to the throne, including presiding over the state opening of Parliament in May. It was the first time since 1963 that the Queen did not attend the ceremony.

The Queen passed during a fragile moment politically after Prime Minister Boris Johnson’s recent resignation. New Prime Minister Liz Truss travelled on Tuesday to the royal castle in Scotland, to be formally asked to form a government.

She became the 15th prime minister to hold office during the queen’s reign – the first was Winston Churchill.

Life of a queen

Queen Elizabeth II ascended to the throne following the death of her father King George VI on 6 February1952, at just 25 years of age.

She was crowned in June the following year.

In February, the UK kicked off a series of celebrations for the Queen’s Platinum Jubilee, marking 70 years of her service to the British Commonwealth.

Throughout her tenure, the Monarch served as a living link to World War II Britain, presided over a post-colonial era adjustment and saw the country through what some called “a bitter divorce” from the European Union during Brexit.

Saying good-bye

After the announcement of her death, crowds outside Buckingham Palace continued to grow significantly while others braved heavy rainfall at Balmoral.

The official website of the Royal Family was temporarily unavailable immediately following her passing but did post that the Queen had died peacefully.

It added that her son Charles and his wife Camilla, the King and Queen Consort, “will remain at Balmoral this evening and will return to London tomorrow”.

According to news media, there will be a 10-day mourning period before her funeral will take place.

Source: United Nations

UN health agency kicks off meningitis vaccination campaigns in Africa

With the COVID-19 pandemic delaying meningitis vaccination campaigns for more than 50 million children in Africa, the region is at a heightened risk of outbreaks of meningitis type A, the UN health agency said on Thursday.

The World Health Organization (WHO) and partners have launched a roadmap to stop by 2030, bacterial meningitis outbreaks on the continent.

In a race against time, African countries are being urged to rapidly implement the plan before the start of the meningitis season in January, which runs until June.

“More than 400 million Africans are still at risk of seasonal meningitis outbreaks, but the disease has remained off the radar for too long,” said Matshidiso Moeti, WHO Regional Director for Africa

Meningitis is caused by inflammation of the membranes surrounding the brain and spinal cord. Acute bacterial meningitis can cause death within 24 hours and leaves one in five survivors with lifelong disability.

African success story

Historically, type A was the highest meningitis outbreak in Africa.

However, in 2010 the effective MenAfriVac vaccine was developed and deployed throughout the continent.

With WHO and partners’ support, more than 350 million people in 24 high-risk African countries have to date, received the MenAfriVac vaccine.

While meningitis type A accounted for 90 per cent of cases and deaths before 2010, no new cases have been reported since 2017.

Controlling that lethal form of meningitis has led to fewer meningitis type A deaths and while half of meningitis-affected people died in 2004, in 2021, 95 per cent of cases survived.

“The defeat of meningitis type A is of one of Africa’s biggest success stories in health, but the fallout from COVID-19 hampers our drive to eliminate this bacterial infection as a public health threat once and for all, and could lead to catastrophic resurgences,” said Dr. Moeti.

Trending backwards

The pandemic severely disrupted meningitis prevention and control services, with disease surveillance, laboratory confirmation of cases and outbreak investigations all steeply declining.

Based on country reports, WHO found that meningitis control activities were reduced by 50 per cent in 2020 compared with 2019, with a slight improvement in last year.

While no meningitis type A case has been reported in Africa over the past five years, outbreaks still occur and are caused by other types of meningococcal bacteria.

In 2019, 140,552 Africans died from all types of meningitis, with major outbreaks of meningitis type C recorded in seven so-called “meningitis belt countries” since 2013.

And last year, a four-month outbreak in the Democratic Republic of the Congo claimed 205 lives.

Moreover, Africa is the only region to still experience outbreaks and accounts for the highest number of new meningitis cases globally – reporting 100 cases per 100,000 people.

“Aside from the toll on human life, outbreaks negatively impact health systems, our fragile economies, and impoverish entire populations forced to contend with multiple health and socio-economic challenges,” lamented Dr Moeti.

Fighting back

In an ambitious bid to defeat bacterial meningitis in Africa by 2030, the new regional strategy sets out a roadmap for countries to shore up diagnosis, surveillance, care, advocacy and vaccination to eliminate outbreaks, curb deaths by 70 per cent and halve infections.

WHO estimates that $1.5 billion will be required between now and 2030 to implement the plan, which if fully adopted will save more than 140,000 lives every year in the region and significantly reduce disability.

“In prioritizing the response to COVID-19, we must not lose our focus on other health problems,” underscored the senior WHO official, urging countries to “ramp up implementation of the new WHO regional roadmap now”.

Source: United Nations

Secretary Antony J. Blinken Before Meeting with Ukrainian President Volodymyr Zelenskyy

PRESIDENT ZELENSKYY: (Via interpreter) Dear State Secretary, colleagues, first and foremost, I would like to extend words of gratitude for your visit and the visit of your team. It sends a very important signal that confirms the leadership support and the leadership positions of the United States, in terms of their support to Ukraine in this war, for our freedom, for democracy, for our nation, for our people, for our territory in this war against the aggressor, the Russian Federation.

And we are grateful for this signal, for the enormous support you are providing on the day-to-day basis, and we’d like to extend words of gratitude to you personally and to the administration of the President Biden, him personally. I would like also to extend words of gratitude to the Congress of the United States for these very constructive steps of support in many directions – the financial support, which is allocated to ensure the stability of Ukrainian economy, as well as further reinforces the capabilities of our armed forces, which are defending the territorial integrity of Ukraine on the battlefield.

These are very important signals saying that United States are with us. And for us it’s a guarantee of the possibility of returning our territories, our lands. And I highly appreciate your arrival, and I’m sure that we can cover many topics today in a more detailed manner.

SECRETARY BLINKEN: Mr. President, thank you so very much. It’s wonderful to see you again, to see my friend, Dmytro. We speak on the phone frequently, but it’s even better to see him and you in person. This is my fifth trip to Ukraine in this job, the third since Russia’s invasion, if you count as one trip the occasion when Dmytro and I met on the border very early and we stepped into Ukrainian territory.

But Mr. President, we know this is a pivotal moment. More than six months into Russia’s war of aggression against Ukraine, as your counter-offensive is now underway and proving effective, that is of course mostly the function of the incredible bravery, resilience of Ukrainians. We see that on the battlefield every day. We are so pleased that we’ve been able to support your efforts and we’ll continue to do so. But fundamentally what this comes down to, the reason for this success, is that this is your homeland, not Russia’s. And it’s as basic as that.

Mr. President, I am pleased to be able to announce, as we did earlier today, additional support for Ukraine, another $675 million in assistance and supplies that your military is already using to such great effect – rockets, artillery, armed vehicles, anti-tank systems, and more. This is the 20th drawdown, as we call it, and that brings our total commitment in security assistance to Ukraine since February to $13.5 billion.

We also notified our Congress of our intent to provide Ukraine with an additional $1 billion in what we call foreign military financing. This is for longer-term acquisitions of systems. We are also providing $1 billion, additional dollars, of financing for our European allies and partners, who’ve been doing so much to support Ukraine. This will allow the purchase of systems that you need, and others will need, over the longer term to deter and defend against any future aggressions from Russia. It will be the kind of assistance that is durable and enduring, as the prime minister and I discussed. I’m looking forward to an opportunity to hear about the counteroffensive, which is part and parcel of putting you, putting Ukraine, in the strongest possible position both on the battlefield and in the event there is a future opportunity for diplomacy.

Another key aspect of this is the massive cost and the massive consequences that Moscow is being subjected to as a result of its aggression. And I think it’s important to continue to emphasize that because what we see is costs on Russia that are already extraordinary and they’re going to get heavier and heavier. We see its GDP in freefall, anywhere between 9 and 15 percent this year; an exodus of more than 1,000 international companies from Russia, a brain drain of the most talented people from Russia; a huge decline in their imports so that they are unable to replace the weapons that they are using. They are unable to produce the products for their own people that they’ve expected in the past. They’re unable to make the things that they used to export to other countries, and their markets will dry out as a result. And they’re unable to borrow money against their sovereign debt.

So it’s gotten to a point where Moscow is now seeking military assistance from North Korea and Iran as we have systematically choked off their access to inputs elsewhere, and we will continue to exert that pressure until the aggression ceases and Ukraine is fully sovereign and independent.

Across all of these measures, our support – the pressure on Russia, the humanitarian and economic assistance – I think together we’ve proven very effective, and we will keep (inaudible). You have our word and our track record. I should also add this: The rest of the world, of course, has felt the consequences of Russia’s aggression. And one of the consequences has been an increase in food insecurity that was already severe because of climate change and because of COVID. Russia’s aggression added to that problem.

The agreement that was reached that lifted the blockade by Russia on Odesa has already resulted in 100 ships bringing grain and food products to the world, and most of that has gone to what we call the Global South – countries in Africa and elsewhere who are the most in need. President Putin’s threat to discontinue that agreement I think will deeply anger and upset the countries that are benefiting now from Ukraine’s right to export its own food.

Very quickly, Mr. President, in April I pledged that we would reopen our mission at the first possible opportunity. Today, joined by Ambassador Brink, I spent some time with our team at the embassy. It was very meaningful to me to see the American flag flying over the United States embassy. We are committed to it, and I’m glad we did it.

Secretary of Defense Austin and I also promised that we will continue to provide security assistance at the president’s request, and as I mentioned, we’ve since provided billions of dollars. Today, the Secretary of Defense Austin is in Ramstein, Germany where he has been working and coordinating with countries around the world in providing assistance to Ukraine.

I said we’d continue to step up with economic assistance. Since April, we’ve provided about $7.5 billion in economic support that goes directly to your (inaudible), including support for 600,000 teachers, and the school year has now started. And so for your future, for our future together, this is so important. We’ll continue to be there for you.

Finally, Mr. President, I visited a children’s hospital today, and that made very real the costs (inaudible) that you’re suffering, but also what’s at stake – quite literally the future of the country, as represented by those children who are victims of Russian aggression. Their bravery, their courage is incredibly inspiring. It’s clear, Mr. President, that Ukrainians both young and old have extraordinary resolve. So does the United States.

Thank you.

Source: US State Department